Slide 1: Cyclopharm Limited ausbiz Presentation
For personal use only Cyclopharm Limited ausbiz Presentation
Slide 2: Safe Harbour Statement
Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of Cyclopharm Limited and as to the
Slide 3: Australian innovation entering a new era of Nuclear Pulmonology driven by AI
Australian innovation entering a new era of For personal use only Nuclear Pulmonology driven by AI Technegas systems are available now in 67 countries. Direct distribution in 17 countries. Over 5.0 million patient procedures to date US Market – Early stage entry Leveraging global infrastructure with
Slide 4: Fifth consecutive record half — 1H2026 revenue up ~14% to $17.5m
Fifth consecutive record half — 1H2026 revenue up ~14% to $17.5m For personal use only Operating revenue by half (A$m) A diversified, growing revenue base Technegas® USA Technegas® Rest of World Third-Party Distribution 20.0 • Fifth consecutive record half — $17.5m in 1H2026, up ~14% on 1H2025 • Thr
Slide 5: USA Technegas revenue up ~74% — revenue-generating sites doubled to 70
USA Technegas® revenue up ~74% year-on-year — revenue-generating sites doubled to 70 +74% For personal use only USA Revenue (A$m) & Revenue-Generating Sites Revenue (A$m) Revenue-gen. sites Contracted (incl. Jul) USA Technegas® revenue growth 1H2026 vs 1H2025 2.5 100 $2.15m 85 90 70 2.0 80 Revenue-g
Slide 6: Proven clinically validated outcomes in detecting Pulmonary Embolism
Proven clinically validated outcomes in For personal use only detecting Pulmonary Embolism (PE) as measured by sensitivity, specificity, accuracy, NPV & NPV Substantially lower radiation than a single CTPA scan (typically ~1–3 mSv vs ~20 mSv) Growing Beyond PE publications indicate a potential >$1 B
Slide 7: Unique Drug + Device + Service combination = regulatory barrier to entry
Unique Drug + Device + Service combination = regulatory barrier to entry For personal use only Technegas comprises the following components SYSTEM PER PATIENT CONSUMABLES SUPPORT USFDA Drug-Device TECHNEGAS PLUS SYSTEM TECHNEGAS ® SYSTEM PACK Combination product Technegas (Crucible) Technegas® Train
Slide 8: Evolution of Ventilation Imaging
Evolution of Ventilation Imaging PLANAR SPECT SPECT/CT SPECT/CT Future Quantification A.I.2023 For personal use only Applications 1986 8 Lobar distribution of ventilation AI reaching to segmental and subsegmental level analysis leading to chronic condition management and Treatable Trait identificati
Slide 9: Clinically Proven, Globally Established Technology US Locations
1 Clinically Proven, Globally Established Technology US Locations For personal use only Updated US guidelines featuring Technegas 2 expected to accelerate adoption Broad USFDA-Approved Ventilation 3 Imaging Indication (further applications under investigation) 4 Every installation generates revenue
Slide 10: Elite adoption — and growth from within
Elite adoption — and growth from within: “no stronger evidence than a customer expanding Technegas within their network” For personal use only ELITE ADOPTION Trusted by the highest-calibre US hospitals 20 / 20 ~50% ~85% 18 Honor Roll engagement Honor Roll (Top 20) Academic & teaching 100 largest US
Slide 11: Technegas named the preferred ventilation imaging agent in established (and new) markets
Technegas® named the preferred ventilation imaging agent in established (and new) markets For personal use only International Guidelines Key Deliverables: A material shift in the US landscape Endorses the US transition from Planar to • US lung-scintigraphy guidelines have not been SPECT and SPECT/CT
Slide 12: Expanding into exponentially larger addressable markets Beyond Pulmonary Embolism
Expanding into exponentially larger addressable markets Beyond Pulmonary Embolism For personal use only CTEPH COPD Asthma Lung Cancer PRIORITY Chronic Thromboembolic ACTIVE TRIAL RESEARCH RESEARCH Pulmonary Hypertension Chronic Obstructive Bronchial Asthma Pre-surgical Lung Pulmonary Disease Assessm
Slide 13: Established and First in Class Growing MedTech
For personal use only Established and First in Class USA Growth Accelerating Recurring Revenue Technegas Product Growing MedTech Well Established in Nuclear Potential to significantly From single patient expansion Underlying business (ex- Medicine grow the size consumables Indications Beyond PE USA)
Slide 14: Thank You
For personal use only THANK YOU 14
Slide 15: Fifth consecutive record half — USA our growth engine
Fifth consecutive record half — 1H2026 revenue up ~14% to $17.5m For personal use only USA — our growth engine Half-on-half revenue progression (A$m) Revenue (A$m) 1H2026 2H2025 1H2025 vs 1H26 USA TECHNEGAS® REVENUE +74% Technegas® USA ~$2.15m $1.46m $1.24m +74% $1.24m → ~$2.15m · 1H25 vs. 1H26 Tech